There is increasing demand for the inclusion of gut microbiome assessments in clinical trials and clinical trial research. Eurofins ADME BIOANALYSES’ launch of GA-map® Dysbiosis Test, a CE marked standardised gut microbiome test by Eurofins ADME BIOANALYSES will enhance its comprehensive microbiome service offering for its clinical research customers.

Gut microbiome profiling is increasingly required as a surrogate endpoint or exploratory biomarker in clinical trials. This is due both to the impact new pharmaceuticals can have on the microbiome and the fact that the microbiota composition itself may greatly affect the response to treatment. GA provides the first CE-marked and standardised microbiome test to profile and compare an imbalanced microbiota to healthy references. The standardised GA-map Test is based on a pre-determined targets approach (PDT)and is establishing itself as a valuable tool in drug development, clinical research and routine diagnostics.

Ronny Hermansen, CEO, Genetic Analysis comments: “GA is proud to have Eurofins ADME BIOANALYSES as a partner in the clinical research field. To map and unlock the bacteria present in the gut is instrumental for developing better treatment regimes. The GA-map platform will offer a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation”.

This information is such information that Genetic Analysis AS is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the below contact person, for publication on 19 October 2021.